Preclinicai studies utilizing different AAV serotypes have demonstrated efficient gene transfer in animal models and stable correction of hemophilia in murine and canine models has been achieved. Early clinical trial data suggest that achievement of therapeutic levels of clotting factors is feasible in human subjects. However, the latter clinical trials have also underscored two major challenges, namely, a large patient cohort displaying pre-existing humoral immunity against AAV capsids and potential hepatotoxiclty associated with administration of high vector dose. The current proposal is focused on designing next generation AAV vectors that display potentia! to evade preexisting anti-capsid neutralizing antibodies (NAbs) and transduce human hepatocytes with high efficiency. To achieve such, we will utilize three complementary AAV capsid engineering techniques and two translational components, namely, a mouse model with humanized fiver and human serum containing anti-AAV capsid NAbs. In synergy with Project 1 of this PPG, we will first establish the hepatotropism of AAV clades with rationally altered antigenic epitopes in humanized mice. In the second and third aims, we will utilize a novel chemical engineering strategy and a combinatorial directed evolution approach, respectively to mask the antigenicity of hepatotropic AAV vectors. The proposed studies should (a) provide structural insight into the antigenicity and hepatotropism of AAV vectors, (b) humanized AAV vectors for preclinical evaluation in large animal models of hemophilia (Projects 3 &4) and (c) optimized vector candidates for clinical trials.
Eariy clinical trial data suggest that gene therapy of bleeding disorders might be feasible in human subjects. The current proposal is focused on tackling clinically relevant challenges, namely preexisting neutralizing antibodies and the need for humanized AAV vectors validated in translational animal models. This project will enable development of new AAV vectors simultaneously capable of enhanced gene transfer to human liver and escaping nrefixistina humoral immunitv in human suhierta '.
|Xiao, Ping-Jie; Mitchell, Angela M; Huang, Lu et al. (2016) Disruption of Microtubules Post-Virus Entry Enhances Adeno-Associated Virus Vector Transduction. Hum Gene Ther 27:309-24|
|Wang, M; Sun, J; Crosby, A et al. (2016) Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: immediate impact on clinical applications. Gene Ther :|
|Li, Chengwen; Wu, Shuqing; Albright, Blake et al. (2016) Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer. Mol Ther 24:53-65|
|Berry, Garrett E; Asokan, Aravind (2016) Chemical Modulation of Endocytic Sorting Augments Adeno-associated Viral Transduction. J Biol Chem 291:939-47|
|Berry, Garrett Edward; Asokan, Aravind (2016) Cellular transduction mechanisms of adeno-associated viral vectors. Curr Opin Virol 21:54-60|
|Nelson, Christopher E; Hakim, Chady H; Ousterout, David G et al. (2016) In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351:403-7|
|Murlidharan, Giridhar; Crowther, Andrew; Reardon, Rebecca A et al. (2016) Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain. JCI Insight 1:e88034|
|Schreiber, Claire A; Sakuma, Toshie; Izumiya, Yoshihiro et al. (2015) An siRNA Screen Identifies the U2 snRNP Spliceosome as a Host Restriction Factor for Recombinant Adeno-associated Viruses. PLoS Pathog 11:e1005082|
|Goodrich, L R; Grieger, J C; Phillips, J N et al. (2015) scAAVIL-1ra dosing trial in a large animal model and validation of long-term expression with repeat administration for osteoarthritis therapy. Gene Ther 22:536-45|
|Hastie, Eric; Samulski, R Jude (2015) Recombinant adeno-associated virus vectors in the treatment of rare diseases. Expert Opin Orphan Drugs 3:675-689|
Showing the most recent 10 out of 34 publications